Drug intelligence / Profile preview

PE3max

Development stage
Preclinical
Lead developer
Boston Children's Hospital
Modality
CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Gene Addition/Replacement → Gene Therapies
Administration
Ex Vivo
01

Overview

PE3max is an optimized prime editing system designed for high-efficiency genome editing in primary cells, including hematopoietic stem and progenitor cells (HSPCs). Prime editing is a search-and-replace technology that uses a fusion protein consisting of a catalytically impaired Cas9 endonuclease (nickase) and an engineered reverse transcriptase, guided by a prime editing guide RNA (pegRNA). The PE3 system specifically utilizes an additional sgRNA to nick the non-edited DNA strand, which stimulates DNA repair and significantly increases editing efficiency compared to the PE2 system. The max designation refers to architectural optimizations, such as human codon optimization and the addition of multiple nuclear localization signals (NLS), to enhance expression and nuclear import. PE3max has demonstrated potential in correcting pathogenic mutations, such as the HBB-E6V mutation causative of sickle cell disease, particularly when combined with strategies to modulate nucleotide metabolism.

Other names
prime editing system 3 max
02

Targets

DNA

Beyond the preview

Go deeper on PE3max.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PE3max.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call